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Abstract 
 
 
Background: Herpes Simplex Virus type 2 (HSV-2) is a common cause of genital 
ulcers worldwide and has emerged as a co-factor in human immunodeficiency virus 
(HIV) acquisition and transmission.  A study was conducted to determine the 
prevalence of HSV-2, its correlates, the accuracy of reported history of genital ulcer 
disease (GUD) to predict HSV-2 infection and the extent of symptom recognition in a 
clinic population in Johannesburg.  
 
Methods: 210 women aged 18 years or older were interviewed and socio-
demographic, sexual behaviour and clinical information collected. Serological testing 
for HSV-2 and HIV infections was performed, but only where sera were available for 
the latter.  Factors associations with HSV-2 infection were assessed using logistic 
regression to estimate odds ratios (OR) and 95% confidence intervals (CI). The 
sensitivity, specificity, predictive values and likelihood ratios of a history of GUD 
were calculated. 
Results: The estimated sero prevalence of HSV-2 was 73% (95% CI 67% - 79%).  
Few participants, 13/206 (6%) participants had knowledge of genital herpes. Only 
9/203 (4%) participants recognised lesions of genital herpes following education and 
counselling about HSV-2 infection. HSV-2 infection  was associated with older 
age(>25 years of age) OR 2.6 (95% CI 1.4-5.0), spending more than 2 nights away 
from home, OR 6.0 (95% CI 1.0-62.7), having more than 2 sexual lifetime partners, 
OR 2.2 (95% CI 1.1-3.9), a history of an STI in the past 3 months ,OR 3.6 (95% CI 
1.2-9.5) and  HIV infection, OR3.3( 95%CI 1.4-7.9). A history of genital ulceration 
 v 
performed poorly as a predictor of HSV-2 seropositivity; the sensitivity was 7% and 
specificity was 96%.  
Conclusion: HSV-2 prevalence was high and few participants were aware of their 
infection. HVS-2 infection was associated with risky sexual behaviour .A history of 
genital ulcer disease was not sufficient as a diagnostic tool for HSV-2 infection. 
Public health interventions should focus on behavioural modification and increasing 
awareness of genital herpes. HSV-2 management should be incorporated into HIV 
care and STI protocols.  
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Chapter One   Study Background 
 
1.1 Introduction 
The sub -Saharan region remains one of the regions hardest hit by the HIV/AIDS epidemic 
in the world. It is estimated that it contributes 68% (22.5 million) of the people living with 
HIV and women in particular bear the burden of the disease.
 1 
South Africa has a much 
higher HIV /AIDS prevalence in the sub-Saharan region, estimated to be 18.8% compared 
to 6.1% for the region.
2
 The epidemic is fuelled in part by sexually transmitted infections 
(STIs).
2   
Prompt and effective STI case management is one of the cornerstones of STI and 
HIV control and prevention strategy. Population-based trials assessing the impact of STI 
treatment on HIV incidence were conducted in Uganda and Tanzania and showed 
differential outcomes in the two countries. In Mwanza, Tanzania, improved syndromic STI 
case management (treatment according to presenting clinical STI syndromes such as 
vaginal discharge) at primary care clinics reduced the HIV incidence by 38% (95%CI 
15%-55%).
3
   In contrast, trials of mass STI treatment in Rakai, Uganda (at least 3 rounds 
STI treatment for the community) and of a behavioural intervention in conjunction with 
STI syndromic treatment in Masaka, Uganda showed no effect.
4,5
 An attempt to 
understand the contrasting results revealed that differences between the study populations 
(baseline sexual risky behaviour, STI rates and the stage of the HIV epidemic) accounted 
for the discrepancies.
6
 Shorter duration STIs that are amenable to treatment were less 
prevalent in Rakai and Masaka than in Mwanza whereas, longer duration STIs which are  
such as Herpes Simples Virus type-2 (HSV-2) were similar across 3 sites. Unpublished 
data also suggested that most symptomatic ulcers in Mwanza were due to chancroid whilst 
HSV-2 was the commonest cause of genital ulceration in Rakai and Masaka.
6, 7
 The 
researchers concluded that in areas of early, nascent HIV epidemics such as observed in 
 2 
Mwanza, curable STIs play a greater role in HIV transmission.  By contrast, incurable 
STIs such as HSV-2 have a larger impact on HIV spread. HSV-2 has emerged as the most 
prevalent STI pathogen and the most common cause of genital ulcer disease worldwide in 
the past decade.
8,9,10 
Many studies show that HSV-2 infection, even without clinically 
recognised lesions is a risk factor for HIV infection.
8,9
 Modelling studies have estimated 
that more than a third of all new HIV cases are attributable to HSV-2 infection in sub-
Saharan Africa.
11, 12
 
In the developed world, the prevalence is higher in the US than Europe; representing 17%-
24% of the adult population according to the NHANES III survey in the United States, and 
in different European countries ranges from 0.1%-11%.
13  
The prevalence of HSV-2 in the 
adult general population in Sub-Saharan Africa ranges from 30%-80% among women and 
10%-50% among men.
8
 HSV-2 is transmitted sexually, primarily from partners with 
asymptomatic or unrecognized infection resulting in the epidemic proportions seen 
worldwide.
14 
Recently, another study demonstrated that over half of HSV reactivations last 
for 12 hours or less and that these short reactivations are usually asymptomatic and 
associated with rapid appearance and clearance of virus in immunocompetent hosts.
15
 At 
such times, asymptomatic persons shedding virus could unknowingly transmit HSV-2 to 
their sexual partners. 
HSV-2 infection manifests clinically as genital ulcers, a known risk factor for HIV 
infection. The past decade has seen a shift in the epidemiology of genital ulcer disease in 
Africa; in the early 1990s, data published identified syphilis and chancroid as the 
commonest cause of GUD whereas in the past 10 years, studies have been reporting on 
HSV-2 as the main cause of GUD.
16 
In South Africa, the proportion of ulcers due to HSV-
2 increased from 3% in 1989 to 17% in 1994 and 36% in 1998.
17
 A sexually transmitted 
infections microbiological surveillance conducted between November 2006 and February 
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2007 in the Western Cape and Gauteng reported that genital herpes accounted for the 
majority of ulcers where an infectious aetiology was established; 71% in Cape Town; 87% 
in Johannesburg.
18
 Similarly, neighbouring South African countries such Botswana have 
also reported similar trends where 24% of GUD among patients with STIs were due to 
HSV-2 in 1993 increasing to 60% in 2002.
10 
In the developed countries such as Europe, 
the shift in the epidemiology of genital ulcerations has seen an emergence of HSV-1 as a 
more common aetiological pathogen of primary genital herpes than HSV-2.
19
 This 
observation has been attributed to the decline in the seroprevalence of HSV-1 in the 
developed world rendering adults without the immunity of HSV-1 who practice oral sex 
more at risk of primary genital HSV-1 infection. For this reason, it is recommended that 
both HSV-1 and HSV-2 specific testing must be performed in populations at risk of HSV-
1 infection. There have been arguments that this epidemiological shift is due to increased 
diagnosis of HSV-2 with the sensitive assays such as polymerase chain reaction (PCR), the 
widespread use of antibiotics to control STIs resulting in low GUD prevalence and the 
spread of HIV.  
The presence of genital ulcers enhances both the acquisition and the transmission of HIV. 
Paz-Bailey et al reported that several cohort studies have demonstrated that GUD is 
associated with a 7-11 fold increase in risk of HIV acquisition.
10
 HIV acquisition is highest 
among those with recent or incident HSV-2 infection which may reflect the higher severity 
of herpetic ulcers with primary HSV-2 infection and frequency of reactivation in the first 
year of HSV acquisition. In a study conducted in Rakai, Uganda; Gray et al studied the 
HIV transmission rate per sex act and found that the two most important risk factors for 
HIV transmission were the presence of genital ulcers and a higher HIV plasma load.
20 
HIV 
transmission was increased four fold (0.0041 per sex act for those with genital ulcers 
versus 0.0011 for those without genital ulceration; p=0.002) in the presence of GUD. Even 
 4 
in the absence of genital ulcer disease, epidemiologic evidence suggests that HIV and 
HSV-2 manifest synergistic bidirectional interactions. Results from randomised controlled 
trials of herpes suppressive therapy on HIV positive individuals have demonstrated 
reductions in the genital and plasma levels of HIV over a 3 month period, suggesting that 
HSV-2 may play a role in HIV transmission.
21,22
  In addition, HIV alters the clinical 
presentation of HSV-2 infections in HIV and HSV-2 co-infected persons with low CD4 
counts resulting in extensive and slow healing ulcers and lead to high rates of HIV and 
HSV-2 genital shedding. 
Vertical transmission of HSV infection in pregnancy is also associated with a rare but 
serious neonatal morbidity and mortality due to neonatal herpes.
23
 Clinical HSV infection 
in neonates presents with primary vireamia that can lead to fulminate liver disease and 
death. Visible lesions are observed in a minority of disseminated neonatal herpes. The 
likelihood of vertical transmission is higher in primary HSV infection in the mother. 
Contact with infected genital secretions at delivery and intrauterine infections account for 
only 5-8% of all transmissions.
24 
Data on the incidence or the prevalence of neonatal 
herpes in South Africa is limited. A study of mothers and babies with unfavourable 
outcomes performed in the Department of Obstetric and Gynaecology at Ga-Rankuwa 
Hospital, Pretoria in 1999, reported that infection with cytomegalovirus was found to be 
the most prevalent infection compared to HSV-2 infection and the latter played a less 
significant role.
25 
The control of HSV-2 appears to be an important part of HIV prevention strategy, but the 
best way to achieve it is still elusive to researchers. Multicentre clinical trials of episodic 
and suppressive antiherpes therapy for HIV prevention have been undertaken in Africa and 
the USA. The results have been disappointing for the impact on HIV acquisition. The trials 
assessing the impact of suppressive antiherpes on HIV transmission are still ongoing and 
 5 
the results are much anticipated.  The aim of this study is to determine predictors of HSV-
2 infection using data collected as part of a study validating the performance of two HSV-
2 serology assays in a population in the inner city Johannesburg. The validation study was 
part of formative research in preparation for at least two of the suppressive antiherpes 
therapy randomised controlled clinical trials mentioned above. The correlates of HSV-2 
will provide valuable information to help identify individuals to be targeted should the 
intervention prove useful. 
 1.2 Literature Review 
 1.2.1 HSV-2 Seroprevalence 
HSV-2 infection is higher in developing countries compared to the developed countries, 
and within countries and populations is higher among high risk individuals.
8, 26
 In 
northwest Tanzania, women working in bars and facilities close to truck stops had a HSV-2 
prevalence rate of 80%.
27
  Another study conducted in Moshi, Tanzania  among women at 
high risk reported an HSV-2 prevalence of 56,9%.
28 
 The HSV-2 prevalence rate among 
commercial sex workers in Durban, South Africa was 84%.
29
 A population- based study 
conducted among the youth in Carltonville, South Africa reported a HSV-2 prevalence rate 
of 53,3% in females and 17% among males peaking at around 89% and 40% for females 
and males aged 22-24 years.
30  
A community-based randomised controlled trial assessing a 
behavioural intervention among youth aged 15-24 in rural Eastern Cape province in South 
Africa reported a baseline prevalence of 27.6% and 31.0% in the intervention and control 
arms respectively among women and 10.3% and 10.0% among men.
31 
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1.2.2 Contributors to the spread of HSV-2 infection 
The prevalence of HSV-2 infection is increased and sustained by unrecognized and/or 
atypical and asymptomatic infections, which in turn lead to under diagnosis and 
asymptomatic shedding of the virus. Sero-epidemiologic studies often reveal a mismatch 
between the HSV-2 antibody prevalence and recognition of clinical symptoms. Only 10% 
to 25% of individuals seropositive for HSV-2 report a history of genital herpes.
14
 Only 2% 
of Tanzanian women reported a history of genital herpes despite a prevalence rate of 39% 
in a cross-sectional study conducted by Msuya et al.
32
 Clinically apparent ulcers were rare 
amongst a cohort of Kenyan female sex workers despite an HSV-2 prevalence of 77.4% .
33
 
However, when individuals with previously unrecognized HSV-2 infection are educated 
about the clinical manifestations of genital herpes,  about 60% come to recognize typical 
symptoms.
34
 Wald et al reported that 26/42 (62%) female participants and 7/11 (64%) male 
participants who had previously denied a history of genital herpes, reported experiencing 
typical ulcers, blisters and crusts in the genital area following an educational session on 
genital herpes that included viewing photographs.
14 
It is worth noting however that the 
numbers in this study were small and therefore the results should be interpreted with 
caution. 
 
The other reasons genital herpes infection goes unrecognized and under diagnosed is that 
the lesions may be located in difficult to locate anatomical site for the attending health care 
provider especially in females and/ or the presentation may be subtle and non specific 
presenting with dysuria, vaginal discharge and vulval irritation and fissures suggestive of 
other conditions such as candidiasis.
8, 14 
Individuals could still unknowingly transmit HSV-
2 virus. 
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Sub-clinical or asymptomatic shedding refers to the detection of HSV on genital mucosa on 
days without lesions consistent with genital herpes. Individuals with symptomatic genital 
herpes have both clinical and asymptomatic reactivations. It is thought that viral shedding 
in individuals who are unaware that they are infected with HSV-2 is responsible for at least 
70% of HSV transmission.
14 
The rate of asymptomatic genital herpes shedding is 
dependent on the virus type, duration of genital herpes infection and co-infection with HIV. 
Shedding rates are higher with HSV-2 compared to HSV-1 infection. In immunocompetent 
persons the rate of asymptomatic shedding appears to decrease over time but does persist 
for life just as symptomatic reactivation of the virus. The likelihood of asymptomatic 
shedding of the virus is more common in HIV positive individuals than HIV negative 
individuals and correlates with plasma CD4 level. In a cross sectional study of HIV 
positive women, the occurrence of HSV-2 shedding was four fold more common among 
women co-infected with HSV-2 and HIV compared with HIV negative women (OR4.1, 
95% CI 1.0-27.4). The rate of total shedding also increased as the CD4+ cell count declined 
(p=0.025).
35
 
 
1.2.3 Risk factors for HSV-2 infection 
Epidemiologic studies in both the developing and developed countries have consistently 
identified correlates of HSV-2 that can be attributed to frequent sexual activity and 
cumulative exposure. However published data on risk factors for HSV-2 infection is 
limited in South Africa. These risk factors can be categorized as socio-demographic [older 
age, female gender, low education status, socio-economic status (low income among 
females and high income among men)], behavioural (number and choice of sexual partners, 
duration of relationships, sexual frequency, knowledge of partner‟s serostatus and condom 
use).  
 8 
Socio-demographic factors 
Most epidemiological studies have demonstrated that HSV-2 infection increases with age, 
increasing from negligible levels in children younger than 12 years to as high as 80% in 
sexually active years thereafter leveling off after 40 years of age (see table 1). This trend of 
increasing HSV-2 infection with age is due to the cumulative increase in the number of 
sexual partners and the chronic nature of HSV-2 infection.  HSV-2 has also been 
consistently found to be higher in women than in men. The reason for this difference can be 
explained by biological factors such as the large female genital mucosal surface area that 
increases the risk of acquisition and the tendency for young women to choose sexual 
partners who are older than them.   
Education, socio-economic status and religion have commonly not been associated with 
HSV-2. However, a study conducted in Tanzania reported a high prevalence of HSV-2 
infection among men with low level of education but not in women.
36  
 Low level of 
education represents lack of access to information and resources to help control STIs 
including HIV resulting in riskier sexual behaviour.    
 
 
Behavioural factors 
HSV-2 is sexually acquired and acquisition indicates sexual activity. A higher number of 
lifetime sexual partners have consistently been associated with HSV-2 infection in both the 
developing and developing countries (see table 1), which is consistent with most STIs and 
indicates that the risk of HSV-2 increases with every sexual exposure. In a cross-sectional 
study conducted between Brazilian and Filipino women participating in a cervical cancer 
trial, HSV-2 prevalence was higher among Brazilian women compared to Filipino women 
and was largely explained by the differences in sexual behaviour of women and their 
husbands. Brazilian women who reported 2 lifetime sexual partners and a husband who 
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occasionally had other sexual partners had a higher risk of HSV-2 infection [OR 2.7 (1.0-
7.20)] and [OR 4.8(2.0-11.4)] respectively.
37 
 
 However, other studies have shown an association between HSV-2 and a lower number of 
reported lifetime sexual partners (see table 1). This variation is likely due to dynamics in 
sexual mixing patterns, age at sexual debut, condom use and the presence of other STIs in 
different population groups. It is also probable that in a background of high HSV-2 
seroprevalence in the community, the individual risk behaviour is not a risk factor given 
that the likelihood of having an infected partner is high even among those with fewer 
partners.   The earlier age of sexual debut is a marker of a longer period of sexual activity 
and therefore exposure to HSV-2. Similarly, factors such as duration of sexual relationship, 
increased sexual frequency and being in a HSV-2 serodiscordant relationship, all of which 
are markers of sexual activity and exposure are associated with HSV-2 infection. 
Consistent and correct condom use was found to be protective in susceptible women in 
HSV-2 sero-incident study. In an ineffective candidate vaccine study of HSV-2 among 
HSV-2 serodiscordant couples, use of condoms for more than 25% of sex acts was 
protective for women (adjusted hazards ratios (HR), 0.085; 95%CI 0.011-0.67).
38   
Another 
sero-incident study among monogamous heterosexual couples on suppressive antiviral 
therapy showed that there was a beneficial effect of condom use irrespective of the level of 
condom usage.
39
  In this study, the couples who used condoms for 1%-90% of sex acts and 
those who used them for more than 90% of the time had lower HSV-2 transmission rates. 
 
Sexually transmitted infections and HIV  
The association between HSV-2 infection and a history of STIs is a marker of risky sexual 
behaviour and reflects the risk of acquiring multiple STIs during high-risk exposure. In a 
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cross sectional study conducted among urban Tanzanian women aged between 15-49 years, 
a history of syphilis was associated with a higher prevalence of HSV-2 infection [OR 4.7 
95%CI (1.4-4.7)].
32
  Since both STIs cause genital ulcers, it is biologically plausible that 
syphillis predisposes to genital herpes and vice versa; however temporality is a limitation 
of cross-sectional studies and in the above study it was impossible to ascertain which 
infection was antecedent. Kaul et al were able to establish temporality between HSV-2 
infection and other STIs; they demonstrated that prevalent HSV-2 increased the risk of 
acquisition of other STIs in a study conducted among female sex workers in Kenya. HSV-2 
infection increased the risk of Nesseria Gonorrheoa (NG) and syphillis acquisition four 
fold, [Incident risk ratio (IRR) 4.3 95%CI (1.5-12.2)] and [IRR 4.7 95%CI (1.1-19.90] and 
of Trichomona Vaginalis (TV) two fold, IRR 2.3 95%CI 1.3-4. 20].
33
 They postulated that 
the immunological changes in the genital tract associated with HSV-2 trigger a cascade of 
pro-inflammatory cells that increase the susceptibility to other STIs particularly NG. Both 
HIV and HSV-2 infections fuel one another by increasing transmissibility and 
susceptibility.
46
 [see figure 1.1below].
 
One of the biological mechanisms by which HSV-2 
increases the risk of HIV acquisition is through genital ulceration (macro and micro-
ulceration) caused by HSV-2 that creates a portal of entry for HIV. 
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Figure 1.1 HSV-2 and HIV interaction (Courtesy of Delany)  
 
HSV also increases HIV susceptibility in the absence of genital ulcer disease. Recent 
studies show that HSV-2 infection -induced genital inflammation increases the number of 
HIV susceptible target cells in the genital tract mucosa, (CD4 T cells expressing HIV co-
receptor CCR-5 and the cervical immature dendritic cells iDCs expressing co-receptor 
DC-SIGN) even in the absence of genital ulceration or HSV-2 reactivation.
47
 Furthermore, 
the risk of HIV acquisition is greater with recent (incident) HSV-2 infection than with 
prevalent HSV-2 infection.
20, 40, 48
 (see figure 2.2 below). The higher risk of HIV 
acquisition with incident HSV-2 infection is partly due to the severity of primary genital 
herpes infection and more frequent recurrences in the first year of life compared to 
prevalent HSV-2 infection. A study was conducted in India in a cohort of 2732 HIV 
negative participant who were mostly men and had an STI (males) or whose partners had 
an STI (female) in order to assess the impact of prevalent and incident HSV-2 infection on 
the acquisition of HIV. Incident HSV-2 cases were categorized as either recent or remote 
HSV-2 infection. Recent incident infection was defined as HSV-2 acquired in the past 6 
months following a negative HSV-2 serology test and remote HSV-2 infection as HSV-2 
HSV- 2 HIV  
Increased 
susceptibility 
and infectivity 
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infection acquired after study entry but with more than 6 months since a negative HSV-2 
serology test. The adjusted hazards ratios increased with relative timing of HSV-2 
infection from 1.67 (95%CI 1.22-2.30) for prevalent HSV-2 infection to 1.92 (95%CI 
1.15-3.21) for remote incident infection and 3.81(95%CI 1.81-8.03) for recent incident 
infection. 
48
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Figure 1.2 Risk of acquiring HIV by HSV-2 infection status (courtesy of Reynolds et al 
J Infect Dis, 2003) 
A study investigating the impact of prevalent and incident HSV-2 infection on HIV 
incidence was conducted in Durban, South Africa amongst a cohort of 416 female sex 
workers. When HSV-2 was analysed as a time dependent covariate, the risk of HIV 
acquisition was greater immediately after HSV-2 seroconversion, HR 6.0 (95%CI 2.6-
14.0), compared to those who remained HSV-2 positive throughout the study. However, 
the data did not provide conclusive evidence for the differences between HIV hazard ratios 
for prevalent and incident HSV-2 infections, i.e. the temporal sequence of events could not 
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be established.
 29
 The authors concluded that while prevalent and incident HSV-2 infection 
has been shown to increase the incidence of HIV in men, the evidence is less convincing 
for women.
29
 
The mechanism by which HSV-2 increases the risk HIV transmission is thought to be due 
to clinical episodes of genital herpes, which create a direct portal exit for HIV.  HIV and 
HSV can co-infect lymphocytes and regulatory proteins resulting in up regulation of HIV 
replication, which in turn increases the shedding of both HSV-2 and HIV and increases 
infectiousness.
46
   Ex vivo studies aiming to elucidate the mucosal immune interactions of 
HIV and HSV-2 in the genital female tract established that HIV-1 infection was associated 
with the depletion of cervical iDCs in persons co-infected with HSV-2 and HIV which was 
independent of the HIV disease   stage.
47 
  The cervical iDCs are an important local 
immune control of HSV-2 infection. This depletion was associated with an increase in 
HSV-2 genital tract reactivation which in turn was associated with high HIV shedding 
levels. 
HIV changes the natural history of HSV-2 infection.
46    
 Persistent anogenital lesions were 
among the first opportunistic infections described among those with AIDS. The natural 
history of HSV-2 infection will be explored further below. 
1.2.4 Natural History of Genital Herpes 
Herpes simplex viruses (HSVs) are enveloped, linear, double stranded DNA viruses whose 
only hosts are humans. There are two types of the virus; type 1 (HSV-1) normally acquired 
in childhood and adolescence and type 2 (HSV-2) which is sexually transmitted, but either 
type can infect a person anywhere on the skin. Herpes simplex viruses are transmitted via 
close contact with infected bodily fluids such as saliva, genital fluids or fluid from active 
lesions. Exposure of the virus at mucosal surfaces or abraded skin facilitates entry and 
replication of the virus.   They establish latency in sensory ganglia following initial 
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acquisition causing an infection that persists for life. Activation of the viral genome may 
occur resulting in viral replication and redevelopment of herpetic lesions in some instances, 
a process called reactivation. Most genital herpes is caused by HSV-2 although genital 
infections with HSV-1 are increasingly recognized; half of new cases in the developed 
countries are due to HSV-1.
19
 The primary stage of genital herpes infection is characterized 
by severe ulceration often presenting as multiple painful ulcers.  
Not all cases of newly acquired HSV-2 infection present with clinically apparent lesions. In 
a study of a HSV-2 candidate vaccine conducted in the USA, of the 155 cases of newly 
acquired HSV-2 infection, only 57(37%) were symptomatic and the rest 98 (63%) were 
asymptomatic.
49
   Eighty five of the 98 asymptomatic cases were followed up for 45 days 
and 13 of the individuals (15%) had clinical reactivation of the disease.  Thirteen percent of 
those that were symptomatic and 30% of cases with reactivated genital herpes presented 
with atypical symptoms that were not immediately suggestive of genital herpes. In this 
cohort, previous HSV-1 increased the frequency asymptomatic HSV-2 seroconversion but 
did not reduce the frequency of acquisition of HSV-2 infection. It is likely that the presence 
of HSV-1 antibodies mask the symptoms of HSV-2 infection resulting in poor recognition 
of infection. This observation is probably due to the fact that antibodies for one type of 
HSV seem to provide partial protection against infection with other serotype. The 
recurrence of ulcers is frequent in the first year following the acquisition of HSV infection 
and may be milder than the initial episode and may become less frequent over time.   
The clinical manifestation of genital herpes often does not follow the described typical 
presentation of a prodromal illness that precedes the development of vesicles and later 
ulcers. Atypical presentations are common, vesicles may not form and instead fissures, 
cracks and crusts manifest. Clinical diagnosis of genital herpes is neither sensitive nor 
specific even for the most experienced clinician, leaving many patients unaware of their 
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affliction.
50, 51
   In the candidate vaccine study mentioned above, only 39% of new genital 
herpes were accurately diagnosed on clinical evidence by experienced physicians. A 
further 20% were inaccurately diagnosed as genital herpes in people who did not have 
genital herpes. 
1.2.5 Laboratory diagnosis of HSV infection 
Because clinical diagnosis is often inaccurate, it is important to have HSV-2 diagnostic 
tests that are highly sensitive and specific. Viral culture is widely available and has been 
the gold standard for the diagnosis of HSV infection in patients who present with ulcers or 
other mucocutaneous lesions. Viral culture is highly sensitive for differentiating between 
HSV-1 and HSV-2 but insensitive for the detection of HSV from genital ulcers. Isolation 
of the virus is easier in the vesicular or early ulcerative stages but sensitivity declines 
rapidly as the lesions begin to heal. Polymerase chain reaction (PCR) testing for HSV 
DNA has greater sensitivity and relative affordability when compared to HSV culture and 
has overtaken as test of choice.
52    
It has a sensitivity of  >95% compared with 75% for 
culture. However the limitation for both tests is that they only focus on those with lesions, 
which is only the tip of the iceberg in genital herpes infection. 
 Sero-epidemiologic studies in the past were hampered by the lack of accurate and easy to 
use tests for the detection of antibodies against HSV-2 in different populations. Type –
specific serologic tests based on glycoprotein G antibodies are the tests of choice to 
establish HSV infection when no lesions are present, but are still inaccessible in 
developing countries due to high cost. These tests have been evaluated in developed 
countries and their sensitivity against Western Blot ranged from 93%-100%, and 
specificity ranged from 95%-100%.
 10    
There have been concerns with the performance of 
some serologic tests in African sera due to observed low specificity,
53, 54 
and therefore, 
these tests require validation in other populations. Universal screening for HSV-1 and 
 16 
HSV-2 in the general population is not indicated. The challenges to serologic testing is that 
the tests do not indicate when the infection was acquired, nor does it confirm the diagnosis 
of a lesion as due to genital herpes; other aetiologies for GUD such as syphilis and 
chancroid should still be excluded. The other limitations in performing both the HSV PCR 
and serology tests for routine management of patients with genital herpes infection in 
resource poor countries is costs and the technical expertise required for these assays. PCR 
requires sophisticated lab equipment, high level of technical expertise and strict quality 
control. 
The potential benefits for testing is that newly infected HSV-2 persons would be counseled 
about the increased risk of HIV acquisition. Routine screening for HSV-2 in populations 
with high HSV-2 and HIV infections such as observed in developing countries is also 
hindered by the cost and poor evidence supporting the use of anti-herpetic as a strategy for 
HIV prevention.  
1.2.6 Intervention Options 
Prevention of HSV-2 infection is of public health importance in the developing countries 
given that HSV-2 and other STIs including HIV infections share similar risk factors such as 
age, mobility, early age of sexual debut and high number of sexual lifetime partners and 
that HSV-2 is a cofactor in HIV transmission and acquisition.  
 
Primary prevention 
Ideally an effective vaccine would be the primary preventive method of choice to reduce 
the acquisition of genital herpes or the severity of HSV disease at an individual level, and 
potentially the reduction of the burden of both HSV and HIV infections at a public health 
level. Currently there is no effective vaccine. Three candidate vaccines have been 
investigated and none were effective. One of the candidates, an HSV-2 glycoprotein D 
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vaccine based on alum morpholine as adjunct showed efficacy of 40-60% for clinical 
disease and HSV-2 transmission only in women who were HSV-1 and HSV-2 seronegative 
at the beginning of the study, but the original study was not powered to show this effect.
55
 
Microbicides which prevent STIs in vitro such as PRO 2000 are another option and would 
ideally offer women a controlled method of preventing HIV and STIs, including HSV-2 
infection. These products are however still under development. 
Behavioural counselling is the only available option and focuses on the modifiable risk 
factors identified in literature review above. Given that HSV-2 infection is a marker of 
sexual activity, educational interventions should target young persons especially women 
and promote behavioural changes who bear the brunt of the disease. Risk reduction 
messages should include delaying sexual initiation, condom use, reducing concurrent 
partnerships, knowing your partner‟s HSV-2 status   and promotion of health seeking 
behaviour for sexual advice and STI symptoms. Interventions aimed at behaviour change 
and ultimately the prevention of HIV have been studied both in Africa and developed 
countries and demonstrated a reduction in the incidence of HSV-2.  A cluster randomised 
controlled trial which assessed the impact of a behavioural intervention (Stepping Stones) 
on the incidence of HIV, HSV-2 and sexual practices in a community in the Eastern Cape, 
South Africa found that the intervention had an impact HSV-2, reducing the incident by 
33% and perpetration of intimate partner violence by males but not on HIV incidence or 
behaviour in women.
31
   The explanation offered by the authors is that younger women 
who tend to have much older sexual partners who have a higher HIV prevalence, lack the 
ability to change their sexual behaviour in the context of unequal gender power relations. 
Intense education campaigns on HIV prevention which targeted young homosexual men in 
Amsterdam observed a strong decline in herpes simplex virus antibodies.
56    
This 
observation was attributed to a change in sexual behaviour. Education campaigns should 
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also aim to increase awareness among the public and health care providers which will in 
turn increase symptom recognition and reduce transmission of HSV infection. 
 
 
Secondary prevention 
Anti-viral therapy available for the treatment of genital herpes offers clinical benefit but 
does not cure the condition. There are two ways in which antiviral therapy can be given to 
treat HSV infections. Episodic therapy is effective when given at the onset of clinically 
apparent disease or during the prodromal phase. It may abort the genital herpes outbreak if 
given during a prodrome or decrease the duration, associated pain and shedding of the virus 
of a clinical episode of genital herpes. Long-term suppressive therapy reduces clinical 
recurrences by 70% to 80% in patients with frequent outbreaks (i.e. more than six 
recurrences per year), and by up to 90% in clinical and subclinical shedding of the HSV. 
414
 
According to mathematical modeling by Blower et al 
57
, in order prevent transmission of 
HSV infection; chronic suppressive therapy is likely to be more beneficial than episodic 
treatment because it reduces both the symptomatic and asymptomatic infectious episodes of 
HSV infection. The authors suggest that concentrating on identifying and treating persons 
with high frequency HSV-2 reactivation, the „virologic core groups‟, could reduce HSV-2. 
Core groups are infected individuals with a high frequency of transmission due to high 
rates of viral reactivation and genital shedding of the virus. Examples of virologic core 
groups are individuals with newly acquired HSV infection, such as sexually active young 
adults and women who acquire primary HSV infection in pregnancy; and individuals co-
infected with HSV-2 and HIV infection. 
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Table 1.0 Summarized Studies of Risk Factors for HSV-2 Infection 
Author  
(Year) 
Study design, Sample 
size & 
Population (Country)  
HSV-2  
Prevalence 
(P) 
/Incidence (I) 
Test  
method 
Risk factor  
(Measure of Effect p-
value/OR/RR with 95%CI) 
Comments 
Ramjee, G 
(2005) 
A cohort of 416 Female 
Sex Workers (South 
Africa) 
 
P = 84.0% 
I = 
35.0%/year 
Gull ELISA i. Increasing age (P=0.001)  
ii. Syphilis (P = 0.004)  
iii. C. trachomatis (P = 0.059) 
1. Primary outcome was HIV incidence 
2. Education levels were reasonably high and not 
associated with HVS-2  
3. Condom use was low and also not associated with HVS-2 
Auvert, B  
(2001) 
Population-based study 
of  718 males and  771 
females  (South Africa)  
P ;M = 17.0% 
P;F = 53.3% 
Type-specific 
Elisa IgG 
(MRL 
Diagnostics 
i. Increasing age 
ii. number of lifetime partners 
1. Data gathered as part of seroepidemiological study of HIV 
infection 
2. Measure of effect not reported 
Tassiopulous, 
K (2006) 
Cross-sectional study of 
1050 females 
(Tanzania)  
P =56.3% Type-specific 
Elisa IgG 
(Focus 
Technologies) 
Similar to risk factors reported in 
the literature 
1. Author only reported that RFs were similar to those 
reported in elsewhere in literature 
2. Measure of effect not reported 
 A cohort of 360 females 14.2/100 
person years 
Type-specific 
Elisa IgG 
(Focus 
Technologies) 
i. HIV infection [3.36 (1.44-7.87)] 
ii. Age of sexual debut [6.00 
(1.39-25.9)]  
iii. Alcohol consumption [1.30 
(1.01-1.68)] 
iv. Partner with other sexual 
partners during follow up [4.91 
(1.39-17.31)] 
v. Ethnic group (Besides Chagga 
and Pare) [2.34 (1.16-4.70)] 
1. Used 1.1 index cut-off value with lower sensitivity equal to 
2. overestimation of  HSV-2 incidence 
3. Condom use not protective 
4. Ethnicity reflects sexual behaviour  
Ketjland EF et 
al (2005) 
Cross-sectional study of 
527 women aged 20-
49years 
(Zimbabwe) 
 
P = 64.5% Type-specific 
Elisa IgG 
Focus 
Technologies) 
i. Non-syphilitic GUD [OR = 9.7 
(1.08-22.34)] 
ii. HIV [OR = 2.92 (1.85-4.65)] 
1. H Ducreyi was not isolated in GUDs. 
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Author  
(Year) 
Study design, Sample 
size & 
Population (Country)  
HSV-2  
Prevalence 
(P) 
/Incidence (I) 
Test  
method 
Risk factor  
(Measure of Effect p-
value/OR/RR with 95%CI) 
Comments 
Brown, J et al 
(2007) 
A prospective cohort of 
2235 females (Uganda) 
P = 51.5% Type-specific 
Elisa 
IgG(Focus 
Technologies) 
i. Being older (P<0.01) 
ii. Less educated (P<0.01) 
iii. Married (P<0.01) 
iv. Past history of genital ulcers 
(P<0.01)  
 1. Baseline data 
  I = 9.6/100 
person years 
Type-specific 
Elisa 
IgG(Focus 
Technologies) 
i. Less educated (P<0.01) 
ii. Polygamous marriage 
(P<0.01) 
iii. Multiple sexual partners/older 
partner prior to HSV-2 
acquisition (P<0.01) 
iv. Having circumcised primary 
partner protective (P=0.04 ) 
v. Pregnant (P=0.01) 
vi. Gonorrhea and Candida 
infections (P<0.01) 
1. Women were more likely to be infected with other STIs at 
the time of HSV-2 acquisition 
2. Male circumcision protection should be explored in more 
studies 
Brown, J et al 
(2007) 
A prospective cohort of 
2296 females 
(Zimbabwe) 
P = 53.2% 
 
Type-specific 
Elisa IgG 
(Focus 
Technologies) 
i. Being older (P<0.01) 
ii. Less educated (P<0.01) 
iii. More lifetime partners 
(P<0.01)  
iv. Past history of genital ulcers 
(P<0.01) 
1. The outcome was HIV incidence 
2. Partner’s HIV and HSV serostatus was not established 
which could result in confounding. 
  8.8/100 
person years  
Type-specific 
Elisa IgG 
(Focus 
Technologies) 
i. Unmarried (P<0.01) 
ii. Transactional sex (P=0.05) 
iii. Report GUD (P<0.01) 
iv. Cervical infections/BV 
(P<0.01) 
1. Neither odds ratios nor risk ratios were reported to assess 
the direction of effect.   
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Author  
(Year) 
Study design, Sample 
size & 
Population (Country)  
HSV-2  
Prevalence 
(P) 
/Incidence (I) 
Test  
method 
Risk factor  
(Measure of Effect p-
value/OR/RR with 95%CI) 
Comments 
Watson-
Jones, D et al 
(2007) 
A cross-sectional study 
of 1143 women working 
in bars and hotels Aged 
16-24 (Tanzania) 
P=66.0%  Type-specific 
ELISA IgG 
(Kalon)  
i. Older age [OR 4.42(2.6-7.6)] 
ii. Less educated [OR 2.96(1.5-
5.6)] 
iii. Number of dependents [OR 
1.48(1.0-2.1)]  
iv. Vaginal douching [OR1.48(1.0-
2.1)] 
v. Age of sexual 
debut[OR1.79(0.9-3.4)]  
vi. Increasing number of sexual 
lifetime partners [OR 5.45 (1.9-
15.9)]  
vii. Consistent condom use[OR 
0.93(0.6-1.5) ] 
viii. Increasing alcoholic 
drinks/wk[OR 3.72(1.6-8.4)]  
ix. Past history of GUD [OR 1.38 
(0.9-2.1)]   
1. The majority of women were infected by age 20. 
2. Alcohol is a marker of risky behaviour   
Kaul R,et al 
(2007) 
A prospective cohort  of 
466 female Sex workers 
(Kenya) 
 
P=77.4 % HSV-2 IgG 
Kalon  
i. Nisseria Gonorrhoea [RR 4.3 
(1.5-12.2)]  
ii. Trichoma Vaginalis [RR 2.3 
(1.3-4.2)] 
iii. Syphillis [RR 4.7(1.1-19.9)]  
1. Study assessing between prevalent HSV-2 and incident 
STIs  
2. Clinical ulcers were rare 
 
Shivaswamy 
KN et al 
(2005) 
A case control study of 
135 STD cases and 135 
controls matched for 
age and sex (India) 
P=89.2%  
 
 
Type specific 
IgG for HSV-1 
and HSV-2 
(UBI-
MAGIEEL 
Enzyme 
Immuno 
assay)  
None of the socio-demographic 
and sexual behavioural risk 
factors were statistically 
significant 
1. The authors concluded that in a setting of high HSV-2 
prevalence, HSV-2 cannot be used as a sexual 
behavioural risk marker. 
2. The small sample size could explain the lack of 
associations. 
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Author  
(Year) 
Study design, Sample 
size & 
Population (Country)  
HSV-2  
Prevalence 
(P) 
/Incidence (I) 
Test  
method 
Risk factor  
(Measure of Effect p-
value/OR/RR with 95%CI) 
Comments 
Msuya SE, at 
al (2003) 
Cross-sectional study of 
382 women 15-49yrs 
(Tanzania) 
 
P=39.0% HSV-2 IgG 
Gull (Meridan) 
i. Presence of GUD [OR 9.7(2.5-
36.9)] 
ii. HIV [OR 2.3 (1.1-4.7)]  
iii. Syphillis [OR 4.7 (1.4-4.7)] 
iv. Genital Ulcers [OR 9.7(2.5-
36.9)] 
v. Age> 30 [OR 3.6 (1.4-9.6)] 
vi. Early age of sexual initiation 
[OR 1.6 (1.0-2.5)]  
vii. >2 sexual lifetime partners 
[OR1.591.0-2.4)]  
viii. History of spontaneous 
abortion [OR 1.9(1.1-3.4)] 
1. Prevalence lower than STD clinic attendees 
2. Risk factors consistent with other studies 
3. Poor recognition of symptoms 
 
Smith J, et al 
(2001) 
A cross sectional study 
181 Brazillian and 371 
Fillipino women; in 
hospital setting 
P;Brazil= 42% 
P;Philippines 
=9.2% 
HSV-2 IgG 
Gull (Meridan) 
Brazil 
i. 2-3 lifetime sexual partners 
[OR OR 2.7(1.0-11.4)] 
ii. 3 lifetime sexual partners [OR 
OR 5.9 (1.8-19.2)]  
iii. Partners with other sexual 
partners [OR OR 4.8 (2.0-
11.4)]  
Philippines 
i. Early age of sexual debut [OR 
OR 5.2(1.7-16.5)]   
1. Age not a risk factor because majority of women were 
older than 40 years 
2. Differences observed in predictors attributed to different 
sexual behaviour between the populations studied 
3. Study supports the use of HSV-2  as a marker past 
sexual behaviour  
Santos FC, et 
al (2006) 
A cross-sectional study 
of HIV + 67 females and 
83 males,  PHC clinic 
attendees (Brazil) 
  
P=52.0%  HSV-2 IgG 
(Focus)  
i. Past history of genital herpes 
[OR 3.8(1.22-12.6)] 
ii. Men with reporting >10 lifetime 
sexual partners [OR 3.5(0.7-
19.9)] 
 
1. Weak associations and small sample size limited control 
for confounding in multivariable analysis 
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Author  
(Year) 
Study design, Sample 
size & 
Population (Country)  
HSV-2  
Prevalence 
(P) 
/Incidence (I) 
Test  
method 
Risk factor  
(Measure of Effect p-
value/OR/RR with 95%CI) 
Comments 
Sucato G, et 
al (2001) 
A cross-sectional study 
of 381 female and male 
adolescents  ages 14-19 
STD clinic attendees 
(USA) 
P=12.0%  HSV-2 
Western Blot  
i. African–American race [OR 
2.3 (1.1-4.8)] 
ii. Female gender [OR 6.0 (2.3-
15.9)] 
1. HSV-2 correlated with demographic rather than 
behavioural factors 
2. Most HSV-2 infections unrecognized just as in adults 
Wald A, et al 
(1997) 
A cross-sectional study 
of 610 females and 351 
Males ages 15-45   
PHC attendees 
 
African American 
comprised of 9% and 
Whites 80% of the total 
population 
(USA) 
 
 
 
P=11.0% 
 
HSV-1 &HSV-
2 Western 
Blot 
 
African- American 
i. Oral sex [OR 2.8(2.4-33.8)] 
 
White 
i. 4-9 lifetime sexual partners 
[OR 3.4(1.2-10.5)] 
ii. >10 lifetime sexual partners 
[10.2 (3.6-32.3)] 
iii. History of STI [OR 2.4 (1.2-
4.8)] 
iv. Married or cohabiting [OR 3.2 
(1.4-7.0) 
v. Low education level [OR 2.7 
(1.4-5.6)] 
 
Men (Both races) 
i. >10 sexual lifetime partners 
[OR 10.4(1.3-83.4)] 
History of STI [OR 3.1(1.1-8.6)] 
1. Racial differences noted among women but not in men 
2. Oral sex a marker of greater number of sexual partners 
and high risk behaviour 
3. Risk of HSV-2 differed by gender and ethnicity 
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1.3.1 Rationale for the study 
The prevalence of HSV-2 has been shown to vary in different population subgroups 
between and within countries with different demographical and behavioural parameters. 
Risk factors associated with HSV-2 infection have been established in developed 
countries and some developing countries, but little is known in South Africa. Because of 
the synergetic relationship between HIV and HSV-2, understanding and identifying risk 
factors will improve knowledge of the epidemiology of genital herpes and inform 
prevention programmes.  Because of variable real-world performance of newer type 
specific serologic tests, a validation of the performance of HerpeSelect® ELISA (Focus 
Technologies Inc., Cypress Hill, Ca) and Kalon HSV-2 gG ELISA™ (Kalon Biologicals 
Ltd, Aldershot,UK) against the gold standard HSV-2 Western Blot (WB) test was 
conducted among women attending family planning services at a clinic in inner city 
Johannesburg in 2003.
53   
The validation study was conducted prior to the implementation 
of RCTs evaluating the impact of suppressive acyclovir therapy on the acquisition and 
transmission in South Africa. We performed secondary data analysis to determine the 
prevalence, risk factors and the extent of symptom recognition in order to inform 
possible intervention for HSV-2 during and after trials. 
 
1.3.2 Purpose of the Research 
The purpose of this study was to examine the influence of certain risk factors on HSV-2 
seroprevalence and the extent of symptom recognition in the population of family 
planning attendees in inner city Johannesburg. 
 
 25 
1.3.3 Objectives 
 To determine the HSV-2 seroprevalence of the clinic attendees in inner city 
Johannesburg. 
 To describe the extent of symptom recognition among this population 
 To assess the risk factors associated with HSV-2 infection. 
 To assess the utility of genital ulcers in predicting HSV-2 infection 
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Chapter Two  Methodology 
 
2.1 Study setting 
This study involves secondary analysis of the data collected as part of a cross sectional 
study evaluating the performance of two serological assays against Western Blot (WB) in 
a South African population. The study was conducted at an urban clinic in inner city 
Johannesburg which primarily offers family planning and STI services; a few primary 
health care services such as voluntary testing and counselling (VCT) are available. The 
clinic is large and with a high patient volume and was therefore ideal as a recruitment site 
for the two randomised clinical trials. It is situated in Hillbrow which is a densely 
populated inner city suburb with high rise buildings characterised by HIV/AIDS, poverty, 
crime and a thriving sex work industry.  The population of Hillbrow is comprised of 
economic migrants from the neighbouring African countries and from rural South Africa. 
It is currently estimated that the population of Hillbrow is close to 100 000 in an area that 
covers only 35 hectares,
58
 but these estimates could be higher due to the constant influx of 
economic migrants and asylum seekers driven by economic and political instability 
experienced by some neighbouring  South African countries. 
 
 
2.2 Study design and sample 
 
A cross-sectional study was conducted between August and November in 2003. This was 
a convenient sample of two hundred and ten consecutive women attending the family 
planning and primary healthcare services at Esselen Street clinic in Hillbrow.  
Participants were included if they were 18 years of age and above (as self reported), 
sexually active (defined as at least one sexual act in the 3 months prior to the interview), 
willing and able to undergo an informed consent process and willing to provide a blood 
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sample for HSV-2 testing. Women were ineligible if they were not willing to undergo the 
informed process or provide a sample for HSV-2 testing. 
   
  2.3 Study methods 
2.3.1 Clinical procedures 
 
An informed consent was obtained from all participants prior to any study –related 
procedures. A detailed history of social, demographic, behavioural, past and current STI 
symptoms was collected using a standardised questionnaire by trained nurse counsellors 
in a private clinical room. Enrolled participants were given an individual standardised 
educational session on genital herpes that included reviewing photographs of herpetic 
lesions. Photographs of both typical lesions (blisters and ulcers) and atypical lesions 
(fissures) were shown and the common symptoms (itching, tingling and dysuria) were 
discussed. In addition, participants were counselled about safer sexual behaviour and 
offered condoms. Information and education on HSV-2 was given prior to collecting 
blood for testing for HSV-2.  Participants were counselled on the implications of a 
positive or negative result and invited to return for results at a later date. Participants who 
reported symptoms including genito-urinary symptoms were referred for treatment.   
 
 
2.3.2 Lab methods 
 
A 10ml specimen of venous blood was collected by a research nurse and sent to the 
laboratory for HSV-2 testing. Participants were tested using Focus HerpeSelect
®
 and 
Kalon tests. Optical density (OD) readings for Kalon and the normalised OD readings for 
HerpeSelect® were recorded and the results categorised as positive, negative and 
equivocal. 
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Subsequent analysis showed that raising the cut off value for HerpeSelect® to 3.4 and 
testing all equivocal results with Kalon as a resolver test resulted in a testing algorithm 
which had high levels of sensitivity and specificity than HSV-2 WB 
51
.   
 For the purpose of this analysis, true positives were those where the HerpeSelect® OD is 
greater than >3.4, and true negatives were those where the HerpeSelect® OD reading was 
< 0.9.The equivocal tests i.e. HerpeSelect® OD readings between 1.1 and 3.4, were 
resolved by Kalon HSV-2 ELISA. 
Following the study, new evidence emerged about the potential role of HIV in reducing 
the specificity of HSV ELISA tests.
54
  Permission was therefore sought to test left over 
sera for HIV and patients were provided with results. HIV testing was performed using 
Abbott AxSYM HIV1/2 Go (Abbott Diagnostics, Wiesbaden-Delkenheim, Germany) at 
the local lab in Johannesburg. There were no equivocal results. 
2.4 Data procedures and management 
Quality control of questionnaires was performed on a daily basis to detect errors and 
confirm any discrepant responses to the questionnaires.  In addition, standard quality 
control procedures were implemented prior to data capture to ensure the integrity of the 
data.   
Data from questionnaires was captured manually into an MS Access database.  
Laboratory results were linked to the behavioural dataset through the participants unique 
study number. Each variable was coded, labelled and a codebook produced for 
referencing. Lab results were provided in electronic database and merged with the 
behavioural data. Data was analysed using STATA (version 9.0, Stat Corp., College 
Station, Texas).Only the participant‟s unique study number (PTID) was used in the 
dataset in order to maintain confidentiality.  
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2.5 Definition of terms 
Condom use 
 
As a measure of consistency of condom use, participants who reported condom use as a 
form of contraception were grouped together with those who reported using condoms as a 
method of preventing HIV infection. Participants who reported that they perceived 
themselves to be at risk of STIs including HIV infection due to lack of condom use were 
categorised as inconsistent condom users. 
 
STI symptoms 
STI symptoms were defined by the conventional genital symptoms such as vaginal 
discharge and genital sores or ulcers. In addition, non-specific genital symptoms such as 
itch or burning in the genital area, flu-like symptoms like fever (particularly in primary 
genital herpes pain in thighs or legs and lower abdominal pain which are recognised in 
literature as symptoms of genital herpes were also included.
14
 
2.6 Statistical Analysis 
The seroprevalence of HSV-2 was calculated as the proportion of cases in the study 
population. The frequency distributions of categorical variables and summary of 
continuous variables were described. The mean, standard deviation (SD) and range of all 
continuous variables was reported. In the cases where continuous variables were 
asymmetric or skewed, medians were reported with inter-quartile ranges (IQR) for 
summary measures. The primary outcome variable, (HSV-2) was dichotomised into a 
binary response and coded as 0= HSV-2 negative and 1= HSV-2 positive. 
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Assessing the value of using a history genital ulcer disease (GUD) as a diagnostic test to 
predict HSV-2 seropositivity 
The accuracy of a past history of genital ulcer disease in predicting HSV-2 infection was 
assessed using test characteristics such as sensitivity, specificity, predictive positive 
value, negative predictive value and the likelihood ratios. The validity of a past history of 
GUD was of particular interest since it would be a cost effective, easy to use and 
accessible diagnostic tool to identify individuals infected with HSV-2 who would benefit 
from suppressive prophylactic acyclovir therapy should the randomised clinical trials 
proved efficacious instead of the “gold standard” HSV serology which is expensive and 
less widely available. 
54
  
The Likelihood Ratio (LR) is commonly used in clinical epidemiology and expresses the 
magnitude by which the probability of a diagnosis in a given patient is modified by the 
test results; it does not prove that the patient has the condition but increases or decreases 
the odds of that diagnosis by a certain factor. 
55 
 
LR1-10: There is a weak association between a positive test and the disease and the test 
should be used with caution. 
LR>10: There is a strong association between a positive test and the disease of interest.   
LR<1: The smaller numbers signify a low risk of having the disease following a negative 
result.  
 
Analysis of outcome 
 
Cross- tabulation (2x2) of the primary outcome variable and the exposure variable were 
carried out. Continuous variables were categorised so that roughly an equal number of 
observations would be in each category. Associations between primary outcome variable 
and exposure variables were explored in univariate analysis using the Pearson‟s chi 
square test (
2) or the Fisher‟s exact test. Both the Pearson‟s chi square and the Fischer‟s 
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exact tests are dependent on the sample size and the Fisher‟s exact test is useful when the 
some of the cells have small (>5) observations. The measure of association was expressed 
as odds ratios (OR) with 95% confidence intervals (CI) 
 
Adjusting for confounders 
 
Confounding occurs when there is an apparent relationship between a risk factor and an 
outcome. A confounder that was determined a priori was age. Since HSV-2 antibodies 
remain for life in infected people, older participants will be more likely to have antibodies 
from previously acquired HSV-2 infection. Age was adjusted for in order to avoid 
overestimation in older participants and underestimation in younger participants thus 
allowing comparison of the risk of HSV-2 infection. Selected factors that were 
statistically significant at level above 0.05 in the univariate analysis were stratified by age 
using stratified (Mantel-Haenszel) analysis. The risk factors were stratified by those that 
were younger or equal to 25 years of age or older than 25 years of age. 
 
Power Analysis: 
A sample size of  N=125 would have 99% power to detect an HSV-2  prevalence of 73%,  
assuming a 55% HSV-2 prevalence based on the results of  a population –based survey 
conducted in Carltonville 
30  
at a 5% alpha (significance level). A smaller sample size, 
N=57 was required for a power of 80%; therefore the study was sufficiently powered to 
detect an HSV-2 prevalence of 73%.  
2.7 Ethical Considerations 
 
 The informed consent process was conducted in the language of the participant‟s choice 
(English, Zulu, Sotho) prior to any study related procedures. Key elements of the 
informed consent process such as voluntary participation, the option to withdraw without 
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any consequences, confidentiality, reimbursement for time and travel and risks and 
benefits of participation were dealt within the informed consent process and counselling. 
Ethics approval (M 03-003-09) in accordance with the guidelines on human 
experimentation was obtained from the University of Witwatersrand and the London 
School of Hygiene and Tropical Medicine (LSHTM) for the validation research study 
respectively. The information on the validation study is in the process of being published 
in a peer review journal. 
The student sought approval from the Reproductive Health and HIV Research Unit 
(RHRU) for secondary data analysis. The student also sought clearance from the 
University of Witwatersrand for the secondary data analysis (see appendix 2). The 
approval of the original study is also attached (see appendix 3) 
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Chapter Three   Results 
 
 
3.1 HSV-2 prevalence 
A total of 210 participants were enrolled into the study. Of these participants, 153 [73%, 
95%CI 67-79] were HSV-2 antibody positive. The prevalence of HSV-2 rose sharply 
from 56% among those less than 20 years of age to almost 95% among those between 
30-35 years of age. Of the participants that had sufficient samples left for HIV testing the 
prevalence of HIV was 52% (CI 43%-60%). Figure 4.1 shows the prevalence of HSV-2 
and HIV by age group. The rate of HSV-2 and HIV co-infection was 45% (CI 37%-54%) 
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Figure 3.1 Prevalence of HSV-2 and HIV by age group 
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3.2 Participant characteristics 
 
Table 3.1 Descriptive characteristics of population 
Characteristic No. of women Percent (%) 
Total N=210 
Age (years)     
Mean (range) 25.6 (17-46)   
Home Language     
Zulu 59 28.1 
Ndebele 59 28.1 
Sepedi 29 13.8 
Xhosa 17 8.1 
Tswana 14 6.7 
Sotho 10 4.8 
Other  22 10.4 
 Level of Education      
Primary 12 5.7 
Secondary 143 68.1 
Post-Matric 55 26.2 
Source of income     
Yes  67 31.9 
No 143 68.1 
Ownership of commodities     
Radio 175 83.3 
Television 150 71.4 
Car 23 10.9 
Other South African languages such as Tsonga, Seswati, English and Afrikaans 
 
  
Table 3.1 shows some of the socio demographic characteristics. All 210 participants were 
African women. The mean age of the studied population was 25.6 years ([SD] 4years).
a
  
The majority of the participants were older than 25 years of age (56.2%); mostly spoke 
Zulu and Ndebele; and were well educated. Despite their high level of education only a 
third reported having a source income derived from the informal sector (street vendors or 
domestic or child care workers or labourers) and formal sector (hotel or retail or security 
officers).  
 
Despite the high impoverished state, levels of ownership of commodities such as a radio 
and a television set were relatively high, 175 (83%) participants reported owning a radio 
                                                 
a
 Even though one of the inclusion criteria was age 18 years and above ,one participant reported her age as 
18 years because she was turning 18 on the year of the interview although her calculated age was 17. 
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and 150 (71%) owned a television set. The participants owned a median of 2 commodities 
(IQR 1-2 commodities). Few, 10 (5%) participants reported not owning any commodities. 
As expected of a population of low socio-economic status, most participants did not have 
access to ready cash nor could they afford private health care. One hundred and thirty five 
(65%) said that they would find it very difficult to access R100 for medical expenses and 
151(72%) reported using public health care facilities to access healthcare. 
 
Overall, 57% of the participants were born in South Africa. Three quarters of those 
interviewed reported Hillbrow as their primary residence and had been living in their 
primary residence for a median of 24 months (IQR 9-36 months).  
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In addition, 83 (39%) of those interviewed reported having a second household or 
residence. The proportion of South Africans who had another household was higher,67 
(80%) compared to non South Africans 19(20%) The second households were located 
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either within Gauteng, possibly in the peri- urban areas or spread throughout other 
provinces in South African as shown in figure 4.2 above. Those participants who reported 
having another household travelled an average of 12 times per year (IQR 2-18 times per 
year) visiting the second residence. Overall, 46/210 (22%)  participants reported  
spending an average of 2 nights away from their primary residence (IQR 1 – 4 nights) in 
the past month irrespective of whether they owned a second residence elsewhere or not.  
3.2.1 Sexual Behaviour 
The mean age of coital debut reported by this population was 18 years of age (SD 
2years). Participants reported first sexual intercourse as young as 12 years, and as old as 
26 years. All participants interviewed had initiated sexual intercourse.  The number of 
lifetime sexual partners ranged from 1-35 with a mean of 3.4 partners.  
Only 32 (15%) participants were married. The majority of participants, 112 (57%) 
reported being in a stable relationship but not cohabiting with their partners.  Married 
participants reported the longest median duration of sexual relationship in months (84 
months; IQR 42 – 120) compared to those not married (24 months; IQR 12 – 48) and 
those in casual relationship (5; IQR 3 - 12). A small proportion, 16 (7.7%) reported 
having more than one sexual partner in the past 3 months with the median number of 
multiple sexual partners being 1 (IQR 1-2).  Of the participants involved in multiple 
sexual relationships, only 2 (12.5%) admitted to having sex in exchange for money. 
Consistent condom use was reported by 23 (41,8)%
b
 of the studied population.  
 
                                                 
b
 Condom use not asked of all participants 
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3.2.2 Self reported history of past and current STI symptoms 
A series of both unprompted (open) and prompted (closed) questions were asked of 
participants about genital symptoms. When participants were asked in an open ended 
manner if they had “any problems in the genital area”, 20 (10%) reported symptoms at the 
time of the interview. The most common symptom spontaneously reported was genital 
itch, reported by 8 out of 20 (40%). When the open-ended questions were followed by the 
enquiry of the presence of specific symptoms amongst all the participants, genital itch 
remained most common, but now lower abdominal pain was equally common 
Only 5 of the 20 participants (28%)
c
 with symptoms at the time of the interview had 
sought treatment for their symptoms and all had visited a local public clinic. Overall, 44 
participants (21%) reported having genital symptoms in the past 3 months and of these, 
the majority 29 (66%) had multiple STI symptoms.  
 
3.2.3 Specific history of genital ulcer disease (GUD)  
Table 3.2 The frequency of symptoms* associated with genital ulcer episodes (for the 
13 participants who reported symptoms) 
 
 
*Symptoms are not mutually exclusive; they will thus not add up to 13 
§ BOM: Burning on micturition 
∞Other: fissure, pain in the thigh, lower abdominal pain 
 
                                                 
c
 Data missing for 2 participants 
Symptoms associated with GUD Frequency Percent 
Genital tingling 9 27.3 
Blisters 7 21.2 
Abnormal vaginal discharge 7 21.2 
BOM 
§
 4 12.1 
Other
∞
  6 18.2 
Total number of symptoms 33 100.0 
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Overall, only 13 (6%) participants reported a history of GUD. Of these participants, very 
few,2(20%)
d
 reported experiencing recurrent episodes of GUD. None of these participants 
experienced more than 6 episodes of GUD per year. A range of clinical symptoms 
associated with presence of GUD were reported by participants (see table 3.2). The most 
frequently cited symptom was genital tingling. Only 4 of the 13 (2.3%) participants were 
diagnosed by a healthcare provider with genital herpes. In all cases, the diagnosis was 
made clinically by a doctor or nurse. No case had serology test or a laboratory test 
performed to isolate the causative agent of genital ulcers. Even though the participants 
who had received a diagnosis of genital herpes reported that they were treated with 
specific anti-herpetic treatment, none knew the name of the treatment received.  
Participants who reported a history of genital ulceration were further asked if they 
engaged in sexual activity during clinical episodes of genital herpes; 9 (69%) reported 
that they continued having sex during genital herpes episodes. Of these participants, 
5(55%) reported that they always or sometimes used condoms, whilst the rest reported 
that they seldom or never used condoms. Reassuringly, disclosure of symptoms seemed 
to be common, with ten participants (83%) reporting that they had disclosed their genital 
ulcer symptoms to their partners. 
 
3.2.4 Genital Herpes Symptom Recognition after Education 
General knowledge or awareness of genital herpes was very poor amongst the studied 
population, only 13(6%) of the participants had ever heard of genital herpes. Only 9
e
 
(4.4%) participants reported having experienced lesions typical of genital herpes 
following education and counselling about genital herpes. All these participants were 
amongst the thirteen participants who reported a history of GUD. Among 194 
                                                 
d
 Data missing for 3 participants 
e
 Out of 210 participants ,data was missing for 7 participants 
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participants who did not report a history of genital herpes, 139b (72%) participants were 
HSV-2 seropositive.  
3.3 Risk factors for HSV-2: univariate analysis 
Table 3.3 Risk factors associated with HSV-2: unadjusted analysis 
 
    
Characteristic  Positive/Total 
 % HSV-2 
Positive  
Unadjusted 
OR(95%CI) 
P value 
Age groups (years)       0.002 
< 25 57/92 62.0 1   
>=25 96/118 81.4 2.6(1.4-5.0)   
 Level of Education        0.119 
Primary 11/12 91.7 1   
Secondary 106/143 74.1 0.3(0.03-2.1)   
Post-Matric 36/55 65.4 0.2(0.02-1.4)   
Source of income       0.691 
No 103/143 72.0 1   
Yes 50/67 74.6 1.1(0.59-2.2)   
          
Mobility:         
Nights spent away from primary 
residence       0.024 
1-2 nights 15/24 62.5 1   
>2 nights 20/22 90.9 6(1.0-62.7)   
Visit other household       0.834 
visit 1-4 times/year 29/39 74.4 1   
visit>4 times/year 26/36 72.2 0.9(0.3-2.8)   
Age (years) of sexual debut       0.071 
<15 12/16 75.0 1   
16-20 125/172 72.7 0.9(0.3-2.9)   
>20 15/21 71.4 0.8(0.2-3.6)   
Lifetime number of sexual partners       0.009 
1-2 55/87 63.2 1   
>2 98/123 79.6 2.3(1.5-3.4)   
Condom Use       0.039 
Yes 9/17 52.9 1   
No 26/32 81.2 3.8(1.0-14.0)   
Past history of STI       0.005 
No 114/166 68.7 1   
Yes 39/44 88.6 3.6(1.3-9.5)   
Past history of genital ulcer 
disease(GUD)       0.289 
No 140/195 71.8 1   
Yes 11/13 84.6 2.1(0.4-10.1)   
HIV infection       0.004 
HIV negative 48/70      68.6 1   
HIV positive 66/75      88.0 3.3(1.4-7.9)   
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Table 3.3 shows the association between HSV-2, socio demographic, sexual behaviour 
and clinical characteristics. Older age (> 25) was significantly associated with HSV-2 
seropositivity [OR 2.6, 95%CI 1.4-5.0]. Mobility appeared to be associated with an 
increased risk of HSV-2 infection. Participants who spent more than 2 nights away from 
home in the past month had greater odds of infection (OR=6; 95%CI 1.0-67.2) .Further 
analysis revealed that participants who were HSV-2 positive spent a mean of 3.75 (range 
2.5-4.5) nights away from home, versus HSV-2 negative participants who spent a mean of 
1.72 nights (range 1.1-2.2) away from home. Participants who travelled frequently to a 
second residence did not have an increased risk of HSV-2 [OR 0.9,95%CI 0.4-1.6 
p=0.834]. Non-South Africans had a lesser risk of being HSV-2 positive although this 
was not statistically significant, [OR 0.7, 95% CI 0.3-1.4, P=0.321].Other demographic 
factors such as the level of education, marital and socio-economic status were not 
associated with HSV-2 infection. 
 
On examination of sexual behavioural characteristics, the participants who reported more 
than two lifetime sexual partners had a two fold increased risk of being HSV-2 positive 
[OR 2.3, 95%CI 1.5-3.4, P=0.009] compared to those who reported one to two 
lifetime sexual partners. Inconsistent condom use and the age of sexual debut were 
not associated with HSV-2 infection in the studied population. A past history of an STI as 
well as HIV infection were associated with HSV-2 infection, [OR 3.6, 95% CI 1.3-9.5, 
p=0.005] and [OR 3.3, 95% CI 1.4-7.9, p=0.004] respectively. A past history of genital 
ulcer disease was not associated with HSV-2 infection. 
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Table 3.4 Age-adjusted Odds Ratios of HSV-2 seropositivty with factors significant at 
p<0.05 
Independent variable  *cOR **aOR 95% CI P-value 
Mobility; >2 nights  6.0 6.6 1.0-41.2 0.031 
>2 lifetime sexual partners 2.2 2.0 1.1-3.9 0.027 
Past history of STIs 3.6 3.6 1.2-9.5 0.010 
HIV 3.4 3.2 1.3-7.7 0.008 
*cOR= crude Odds Ratio                **aOR= adjusted Odds Ratio 
 
Table 3.4 shows the age-adjusted odds ratios of HSV-2 seropositivity with selected 
factors. The difference between adjusted ORs and the crude ORs was less than 10% 
indicating that there was no significant confounding.   
 
 
3.4 The utility of   GUD history in predicting HSV-2 seropositivity 
Table 3.5 Cross tabulation for calculating the accuracy of a GUD history in 
predicting HSV-2 infection 
 
History of GUD HSV-2 Pos HSV-2 Neg Total 
Yes 11 2 13 
No  140 55 195 
Total 151 57 208 
 
Sensitivity= 7%    Specificity= 96%  
Positive predictive value (PPV) = 84% Negative predictive value (NPV) = 28% 
Positive likelihood ratio test (LR) = 2.07 Negative likelihood ratio test (LR) = 0.96  
 
A history of GUD would have correctly identified 7% of cases with HSV-2 infection. By 
contrast, specificity was 96%. The PPV was 84% with a negative predictive value of 
28%. The positive likelihood ratio test is 2.07 and the negative likelihood ratio test is 
0.96.  
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Chapter four   Discussion 
 
The aim of the study was to determine the prevalence of HSV-2, its correlates, the utility 
of GUD history in predicting HSV-2 infection and the extent of recognised symptomatic 
herpes in the studied population. 
 
 HSV-2 Seroprevalence 
The prevalence of HSV-2 was very high in this population at 72% (95% CI 67% - 79%). 
Other epidemiologic studies in South Africa have also demonstrated high HSV-2 
prevalence in young female adults in the Eastern Cape (32%)
31
, and Carltonville situated 
west of Johannesburg (53%)
30
, HIV positive individuals (63%)
59
 , and female sex workers 
in Durban (84%)
29
.  The HSV-2 prevalence in this population however approaches that of 
female sex workers.  One of the possible explanations is that demographic characteristics 
suggest that these are young women of reproductive age who are economic migrants but 
are unemployed despite having a relatively high level of education. These participants 
would therefore be vulnerable to high risk behaviour such as exchanging sex for money 
or gifts to for livelihood, which would increase their risk of acquiring STIs including 
HSV-2. However, reported transactional sex was not high possibly due to social 
desirability bias. On the other hand, at high prevalent HSV-2 levels in the general 
population, low rates of partner change are sufficient to sustain the prevalence because 
HSV-2 infection persists for life whereas STIs of brief duration such as gonorrhoea and 
Chlamydia are limited to subsets of the population with high rates of partner change. 
The risk of being infected with HSV-2 was associated with older age, mobility, having 
more than 2 lifetime sexual partners, a past history of STIs and HIV infection.  
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Socio-demographic risk factors 
Significant confounding is present if (aOR-cOR) /cOR = > 20-30%. The difference 
between adjusted ORs and the crude ORs was less than 10% indicating that significant 
confounding was not present. Therefore age was not a confounder but an independent risk 
factor for HSV-2 infection.  
Older age was significantly associated with HSV-2 seropositivity. As has been observed 
in other studies, HSV-2 prevalence increased with age peaking at the 30-34 age group and 
thereafter levelled off after age 40. More than half (56.2%) of the participants less than 20 
years of age had HSV-2 antibodies suggesting that HSV-2 infection occurs during the 
first few years following sexual debut. Therefore, young women should be targeted for 
HSV-2 prevention strategies. The effect of travelling was significantly associated with 
HSV-2. Migration and travel has been observed to be associated with STIs including 
HSV-2 and HIV among migrant women and men in South Africa and other developing 
countries.
8,60   
Travelling may be a proxy of risky sexual behaviour such as having 
multiple concurrent sexual partners which in turn increases the risk of STIs. There was no 
data on recent concurrency collected in the study which would support this observation.  
 
Education and the socio-economic status were not associated with HSV-2 infection and 
this effect has been observed in other seroepidemiological studies.
8,19, 61   
It is possible that 
the overall high level of education and a low economic status in the studied population 
made it difficult to observe associations between HSV-2 and these explanatory variables 
due to lack of power for comparisons.  
 
Behavioural risk factors 
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Participants who reported having three or more lifetime sexual partners had double the 
risk of HSV-2 infection compared to participants reporting fewer lifetime sexual partners. 
The association between lifetime number of sexual partners and HSV-2 is consistent with 
data from the African, US and European countries (see table1) and is a measure of 
increased sexual activity.  
Condom use was not associated with HSV-2 infection. It is possible that condom use was 
not consistent with every sex act but per perceived risky sexual encounter and, thus the 
benefit derived from condom use was lost.  
In other seroprevalent studies, other sexual habits markers such as cohabiting with ones 
sexual partner and early sexual debut were associated with an increased risk of HSV-2 
infection. In this population however, none of these factors were associated with HSV-2 
infection. Being married and cohabiting with a sexual partner is thought to be associated 
with high HSV-2 prevalence due to frequent sexual contact in a HSV-2 serodiscordant 
relationship. The majority of participants (57%) in the studied population were not 
cohabiting with their sexual partners and very few (15%) were married. In addition, their 
partners were not tested for the presence HSV-2 antibodies. Early initiation of sexual 
intercourse has been found to be associated with HSV-2 infection
27, 45, 61
, but not in this 
population. The likely explanation is that, not many reported sexual debut less than 15 but 
on the other hand ,older age of sexual initiation was more likely to be protective (OR<1) 
although this difference did not reach statistical significance. 
 
  Sexually transmitted infections 
As in other studies, the likelihood of HSV-2 infection was found to increase among study 
participants reporting a past history of an STI. If an individual presents with an STI 
chances of having more than one STI are high due to riskier sexual behaviour and having 
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a high risk sexual partner. Participants also reported multiple STI symptoms which might 
translate to infection with more than one STI pathogen. Genital examination and 
laboratory tests to ascertain the aetiology of STI symptoms were however not conducted 
in this study. In addition, HSV-2 confers genital tract immunological changes that 
increase the risk of acquiring other sexually transmitted infections.  The biological basis 
for the immunological changes due to HSV-2 is thought to be due to the intense 
proliferation of proinflammatory cytokines and chemokines which are a final pathway for 
many inflammatory stimuli observed in the female genital tract. These immunological 
changes have been demonstrated to enhance infection by N gonorrhoea amongst others. It 
is possible that control of HSV-2 would not only control HIV infection but other STIs as 
well. 
 
Treatment for STI related symptoms was only sought by 28% of the participants. These 
numbers are disappointing as access to STI and primary health care services is free in 
South Africa. It is difficult to elucidate from the data collected the reasons for this poor 
health-seeking behaviour. A study done in a clinic cohort in Uganda, found that the 
participants‟ decision to seek STI treatment in health facilities might be hampered by 
perceived poor quality of service, overcrowding and inefficacy of treatment prescribed 
especially in the case of recurrent genital herpes symptoms.
62   
At the time of the study, 
anti-herpes therapy was not part of the syndromic case management of GUD in the public 
sector in South Africa and the treatment was therefore likely to be ineffective if HSV-2 
was the causative organism.  
 
A substantial proportion of individuals continued to engage in sexual activity despite the 
manifestation of symptoms and almost half of the women had unprotected sex. This risky 
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behaviour has also been observed in men in a STI clinic in Uganda and in Durban, South 
Africa.
62,63  
This risky behaviour could be an indication of lack of knowledge regarding 
sexual transmission of STIs especially genital herpes as observed in this population or the 
inability to negotiate condom use by women. Another possible explanation is that women 
were not willing to admit to partners that they had a problem, although this is unlikely 
given that most of the participants with genital herpes reportedly disclosed their ailment 
to sexual partners. Whatever the reasons for continuing to engage in sexual activity whilst 
symptomatic are, they can facilitate the spread of both HIV and HSV-2 and are a public 
health concern.  
  
The likelihood of HSV-2 infection was three times higher amongst those with HIV 
infection, and this is consistent with data worldwide. The HIV and HSV-2 co-infection 
rates of 54% could be an underestimate in this population since not all subjects had 
suffient sera for HIV testing. It is not clear which infection comes first but HIV and HSV-
2 co infected persons experience severe and frequent genital herpes symptoms and also 
have higher HSV-2 and HIV shedding from the genital tract.  If antiherpes treatment is 
not included in management of GUD, delayed ulcer healing results in prolonged HIV 
shedding and increased risk of HIV transmission. 
 
 The performance of GUD history in predicting HSV-2 infection 
In the studied population, a history of GUD was not useful in predicting HSV-2 infection 
and would actually lead to under diagnosis of genital herpes. The poor sensitivity of a 
clinical diagnosis of genital herpes is similar to observations made in other studies and 
can be explained by the low recognition or asymptomatic genital herpes. The high 
specificity and PPV indicate that a history of GUD would yield fewer false positive, thus 
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increasing the probability of a person being infected HSV-2 and in turn reduce the 
psychological trauma caused by inappropriate labelling. In addition, overtreatment is less 
likely if a past history of GUD is used to identify participants that would benefit from 
acyclovir therapy which is reassuring in the face of high drug costs. Both the positive and 
the negative LRs confirm that there is no value in the history of GUD in separating those 
who are HSV-2 positive from those that are HSV-2 negative. However, characteristics 
such as high sensitivity and high LR would have been desirable in order to correctly 
detect and treat all participants with HSV-2 infection to prevent transmission of HSV-2 
and possibly HIV infections. This difficulty in using the presence or the history of GUD 
in predicting HSV-2 infection is further complicated by mixed infections with other STI 
pathogens and time to presentation for treatment. 
 
 With HSV-2 currently the leading cause of GUD and the epidemiologic evidence that 
HSV-2 is a co-factor in HIV transmission and acquisition, developing countries are 
currently reviewing STI syndromic management guidelines. However, decision about 
who would benefit from anti herpes treatment and what screening tools, if any could be 
used to identify those most at risk still pose a dilemma for policy makers. RCTs of herpes 
episodic treatment of symptomatic genital herpes were conducted in South Africa, 
Malawi, Ghana and Central African Republic to evaluate the clinical and virologic benefit 
of adding acyclovir in the GUD management guidelines in Africa. According to Nagot et 
al, these studies have shown little impact on ulcer healing among HIV patients and no 
impact on immunocompetent individuals.
64
   The South African trial demonstrated an 
accelerated time to healing of ulcers by one to two days among HIV positive patients who 
presented early, and based on these on the findings, GUD syndromic management 
guidelines have been reviewed to include acyclovir.
66
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In addition, proof of concept clinical trials assessing the impact suppressive antiviral 
therapy among individuals co infected with HSV-2 and HIV all but one demonstrated a 
reduction in both plasma and genital HIV viral load.
64
   These trials used genital shedding 
of HIV as an endpoint measure and were of relatively short duration.  It is hoped that 
transmission of sexually acquired HIV infection can be reduced by anti-herpetic treatment 
judging by the evidence generated by these proof of concept trials if one assumes that a 
reduction in the genital and plasma HIV-1 RNA levels is a proxy for decreased 
transmissibility. The results of two RCTs that measured the impact of suppressive anti 
herpes therapy on HIV acquisition have been published and showed no impact. The 
researchers postulated that poor adherence 
66
 and different acyclovir pharmacokinetics 
67
 
were reasons behind the failure to show effect. Feature health policy will be guided by the 
results of the impact of suppressive HSV-2 therapy among couples infected HSV-2 with 
discordant HIV status, where the index partner is both HSV-2 and HIV-1 infected.  The 
high levels of HIV and HSV-2 co-infection in the studied South African population 
suggest that episodic and possibly long-term suppressive therapy would be of benefit in 
the reduction time to healing of ulcers and HSV-2 and HIV genital shedding for those 
participants who have clinical HSV-2 symptoms if started early.  
 
 Recognition of genital herpes symptoms 
In this population, there was low recognition of genital herpes with few participants 
reporting a diagnosis of genital herpes amongst those with HSV-2 infection following 
education and counselling which included pictures of genital herpes.  
This observation could be explained by the high HSV-1 prevalence common in South 
Africa, which masks the clinical expression of HSV-2. However, HSV-1 testing was not 
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conducted in the studied population and therefore this explanation is ade with caution. It 
has been documented that the recognition of genital herpes symptoms following detailed 
education, counselling about genital herpes coupled with close follow up increased by up 
to 42%-60%.
34   
It is possible that follow up visits might have resulted in increased 
recognition of symptoms were they conducted in this study. 
Of note is the fact that GUD prevalence was low despite the high rate of HIV and HSV-2 
co-infection. Among HSV-2 and HIV-1 dually infected people, HIV-1 alters the natural 
history of genital herpes resulting in extensive and slow healing ulcers especially in WHO 
stage 3 and 4 HIV disease.
46    
Unfortunately, neither WHO staging nor CD4 count testing 
was done in this study. In addition, very few participants reported extensive and frequent 
genital herpes recurrences. It is possible that most of the dually infected women had 
higher CD4 levels and therefore the frequency of symptomatic genital herpes infection 
was not common. Even though recognition of symptoms is essential in the prevention of 
transmission of genital herpes, a herpes transmission study involving highly motivated 
heterosexual couples found that sub-clinical HSV infection was responsible for nearly all 
cases of genital herpes transmission.
68
   Advice should thus be given to patients about 
HSV shedding as part of primary prevention. 
 
 Limitations 
One of the limitations of this study is that which is common to other cross-sectional 
studies; temporality cannot be ascertained. The study also relied on self –reported sexual 
behaviour, history of sexually transmitted diseases including genital ulcer disease which 
are subject to recall bias and social desirability bias in the case of sexual behaviour. 
The sample size had enough power to detect the prevalence of HSV-2 but not enough to 
detect small differences between the groups that were HSV-2 positive from the group that 
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was HSV-2 negative. According Peduzzi P et al, one needs at least ten outcomes for 
every independent variable to be able to convene a multivariate model for multivariate 
analysis.
69
 Because the conditions of having at least ten outcomes for each variable stated 
above was not met in our dataset, a model for multivariate analysis was difficult to 
convene. Finally, this data is based on women attending primary health care facilities and 
thus limiting generalizability of HSV-2 infection rates to the general population.  
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Chapter Five  Conclusion and Recommendations 
 
Conclusion 
In conclusion; the prevalence of HSV-2 seropositivity in this studied population is high 
and knowledge about this disease is low. High risk behaviour such as a higher number of 
partners, a self reported past history of STIs and HIV infection should be used as markers 
to identify those at risk of HSV-2 infection.  
A paradigm shift is required in the management of HSV-2 in South Africa, to include 
anti-herpes treatment, education, and improved clinical skills at primary care. The public 
health challenges are abound however and include, but are not limited to lack of an 
affordable and acceptable serologic test, which population to target for screening and 
increasing accessibility of antiviral therapy. A survey examining barriers to the access of 
acyclovir in the public and private sector in sub-Saharan Africa including South Africa 
was recently completed. Findings were that demand for acyclovir was low due to cost and 
lack of evidence for efficacy.  The cost was USD $1 in the public sector and USD $ 2-7 in 
the private sector.
70    
Acyclovir patent has expired and generic acyclovir should be more 
affordable and the South African trial has provided evidence for efficacy among HIV and 
HSV-2 positive males. In summary, a package of services for people with STIs and high 
risk behaviour should include HIV testing and counselling and for those who test HIV 
positive, provosion of antiherpes treatment because of high HIV and HSV-2 co-infection 
rates. Counselling to improve recognition of herpes symptoms, early initiation of episodic 
anti herpetic treatment and counselling on condom use and abstaining from sexual 
intercourse during herpes outbreaks is also essential.  
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